Jan 09, 2024 / 07:15PM GMT
Rachel Marie Vatnsdal Olson - JPMorgan Chase & Co, Research Division - Analyst
Good afternoon, everyone. This is Rachel Vatnsdal from the life science tools and diagnostics team here at JPMorgan. Thank you for coming to the Danaher presentation. This will be a 40-minute session as we typically do, roughly 20 minutes of our presentation followed by 20 minutes of Q&A. If you do have questions, feel free to either submit them via the app or you can ping me directly. And with that, I will pass it off to Rainer.
Rainer M. Blair - Danaher Corporation - President, CEO & Director
Well, thank you, Rachel, and thank you to JPMorgan for having us, and good morning, everybody, and thank you for joining us today. Before I jump into my presentation, just a quick look at our forward-looking statement advisory here, which you can cruise along with our non-GAAP reconciliation schedule at your own leisure. Now let me get started with just a brief update as to our preliminary results for the fourth quarter of 2023.
Our core growth came in better than expected.
Danaher Corp at JPMorgan Healthcare Conference Transcript
Jan 22, 2024
Already have an account? Log in
Get the full story
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent 
4.6 out of 5 
Trustpilot
Trustpilot
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers